The use of insulin-like growth factor-1 (IGF-1, mecasermin) for treating growth hormone insensitivity syndrome (GHIS) originated with Fujisawa Pharmaceutical (now Astellas Pharma) in Japan, where it was granted Orphan Drug Status for both GHIS and for severe insulin-resistant diabetes in November 1993.